143 related articles for article (PubMed ID: 38513238)
21. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
[TBL] [Abstract][Full Text] [Related]
22. The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
Toptas T; Pestereli E; Simsek T; Bozkurt S; Erdogan G; Karaveli S
J Cancer Res Ther; 2018; 14(3):587-592. PubMed ID: 29893323
[TBL] [Abstract][Full Text] [Related]
23. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.
Kurman RJ; Vang R; Junge J; Hannibal CG; Kjaer SK; Shih IeM
Am J Surg Pathol; 2011 Nov; 35(11):1605-14. PubMed ID: 21997682
[TBL] [Abstract][Full Text] [Related]
24. Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage.
Singh N; Benson JL; Gan C; Anglesio M; Arora R; Faruqi AZ; Hirschowitz L; Kommoss F; Scott K; Trevisan G; Leen SLS; Wilkinson N; Gilks CB; McCluggage WG
Int J Gynecol Pathol; 2018 Jul; 37(4):324-330. PubMed ID: 28787323
[TBL] [Abstract][Full Text] [Related]
25. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
26. Pathology of the Fallopian Tube: Tubal Involvement by Ovarian Tumors and Incidental Findings in the Nontumoral Setting.
Karpathiou G; Chauleur C; Venet M; Clemenson A; Peoc'h M
Pathobiology; 2020; 87(1):37-44. PubMed ID: 31972564
[TBL] [Abstract][Full Text] [Related]
27. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Morrison JC; Blanco LZ; Vang R; Ronnett BM
Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
[TBL] [Abstract][Full Text] [Related]
28. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions.
Wu NY; Fang C; Huang HS; Wang J; Chu TY
Mod Pathol; 2020 Jan; 33(1):29-37. PubMed ID: 31558785
[TBL] [Abstract][Full Text] [Related]
29. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
30. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
31. Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma.
Mittal N; Srinivasan R; Gupta N; Rajwanshi A; Nijhawan R; Gautam U; Sood S; Dhaliwal L
Indian J Pathol Microbiol; 2016; 59(4):481-488. PubMed ID: 27721278
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?
Gao FF; Bhargava R; Yang H; Li Z; Zhao C
Hum Pathol; 2013 Aug; 44(8):1534-43. PubMed ID: 23465279
[TBL] [Abstract][Full Text] [Related]
33. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
34. Fallopian tube origin of supposed ovarian high-grade serous carcinomas.
Diniz PM; Carvalho JP; Baracat EC; Carvalho FM
Clinics (Sao Paulo); 2011; 66(1):73-6. PubMed ID: 21437439
[TBL] [Abstract][Full Text] [Related]
35. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.
Bagby C; Ronnett BM; Yemelyanova A; Maleki Z; Kuhn E; Vang R
Int J Gynecol Pathol; 2013 Sep; 32(5):433-43. PubMed ID: 23896706
[TBL] [Abstract][Full Text] [Related]
36. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings.
Katabathina VS; Amanullah FS; Menias CO; Chen MM; Valente PT; Chintapalli KN; Prasad SR
Radiographics; 2016; 36(3):918-32. PubMed ID: 27163599
[TBL] [Abstract][Full Text] [Related]
37. The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians.
McCluggage WG; Hirschowitz L; Gilks CB; Wilkinson N; Singh N
Int J Gynecol Pathol; 2017 May; 36(3):230-239. PubMed ID: 27801755
[TBL] [Abstract][Full Text] [Related]
38. Ovulation Enhances Intraperitoneal and Ovarian Seedings of High-Grade Serous Carcinoma Cells Originating from the Fallopian Tube: Confirmation in a Bursa-Free Mouse Xenograft Model.
Hsu CF; Seenan V; Wang LY; Chu TY
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682896
[No Abstract] [Full Text] [Related]
39. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
[TBL] [Abstract][Full Text] [Related]
40. Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy.
Ayres C; Ratnayake G; McNally O; Quinn M
Int J Gynecol Cancer; 2017 May; 27(4):703-707. PubMed ID: 28399030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]